Models of respiratory disease symposium

Journal of Inflammation (United Kingdom)

Volumn 10, Issue SUPPL.1, 2013, Pages

  Abbott Banner, Kathy H ^a   Holmes, Anthony ^b   Adcock, Ian ^c   Rao, Navin L ^d   Barrett, Edward ^e   Knowles, Richard ^f  

^a Verona Pharma Plc   (United Kingdom)

^b National Centre for the Replacement   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^e LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^f Stevenage Bioscience Catalyst   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACIDIC MAMMALIAN CHITINASE; ANTIALLERGIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETAMETHASONE; CHITINASE; COLLAGEN; CORTICOSTEROID; FLUTICASONE PROPIONATE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY; MK 7246; PHOSPHODIESTERASE IV INHIBITOR; POLYINOSINIC POLYCYTIDYLIC ACID; PREDNISOLONE; PROTEIN KINASE SYK INHIBITOR; ROFLUMILAST; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VTX 378;

ALLERGY; ALTERNARIA ALTERNATA; ASTHMA; CLINICAL FEATURE; CLINICAL RESEARCH; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DISEASE EXACERBATION; DISEASE MODEL; DRUG INDUSTRY; EOSINOPHILIA; EXPERIMENTAL ANIMAL; HEALTH CARE NEED; HOUSE DUST; HUMAN; MAST CELL; NONHUMAN; NOSE ALLERGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; RESPIRATORY TRACT DISEASE; SYMPOSIUM; TREATMENT FAILURE; UNITED KINGDOM;

EID: 84885415267     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-10-S1-I1     Document Type: Conference Paper

References (21)

1. Animal models of asthma: value, limitations and opportunities for alternative approaches. Holmes AM, Solari R, Holgate ST, Drug Discov Today 2011 16 15-16 659 70 10.1016/j.drudis.2011.05.014 21723955
2. http://www.nc3rs.org.uk/asthmaaward
3. http://www.maths-in-medicine.org/uk/2011/asthma/report.pdf
4. http://www.maths-in-medicine.org/uk/2013-nc3rs/steroids/description.pdf
5. Immunology of asthma and chronic obstructive pulmonary disease. Barnes PJ, Nat.Rev.Immunol 2008 8 183 192 10.1038/nri2254 18274560
6. A new look at the pathogenesis of asthma. Holgate ST, Arshad HS, Roberts GC, Howarth PH, Thurner P, Davies DE, Clin.Sci.(Lond) 2010 118 439 450
7. Biochemical basis of asthma therapy. Barnes PJ, J.Biol.Chem 2011 286 32899 32905 10.1074/jbc.R110.206466 21799015
8. Are mouse models of asthma appropriate for investigating the pathogenesis of airway hyper-responsiveness? Kumar RK, Foster PS, Front Physiol 2012 3 312 23060800
9. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Koth LL, Arron JR, Fahy JV, Am.J.Respir.Crit Care Med 2009 180 388 395 10.1164/rccm.200903-0392OC 19483109
10. Gene expression patterns of Th2 inflammation and intercellular communication in asthmatic airways. Choy DF, Modrek B, Abbas AR, Kummerfeld S, Clark HF, Wu LC, Fedorowicz G, Modrusan Z, Fahy JV, Woodruff PG, et al. J.Immunol 2011 186 1861 1869 10.4049/jimmunol.1002568 21187436
11. Lebrikizumab treatment in adults with asthma. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, et al. N.Engl.J.Med 2011 365 1088 1098 10.1056/NEJMoa1106469 21812663
12. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. McKinley L, Alcorn JF, Peterson A, Dupont RB, Kapadia S, Logar A, Henry A, Irvin CG, Piganelli JD, Ray A, et al. J.Immunol 2008 181 4089 4097 18768865
13. IL-17A induces glucocorticoid insensitivity in human bronchial epithelial cells. Jan ZG, ten Hacken NH, Hoffmann RF, Van Oosterhout AJ, Heijink IH, Eur.Respir.J 2011
14. Asthma phenotypes: the evolution from clinical to molecular approaches. Wenzel SE, Nat.Med 2012 18 716 725 10.1038/nm.2678 22561835
15. Cluster Analysis and Clinical Asthma Phenotypes. Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, Wardlaw AJ, Green RH, Am J Respir Crit Care Med 2008
16. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, D'Agostino R Jr., Castro M, Curran-Everett D, Fitzpatrick AM, et al. Am.J.Respir.Crit Care Med 2010 181 315 323 10.1164/rccm.200906-0896OC 19892860
17. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Bel EH, Sousa A, Fleming L, Bush A, Chung KF, Versnel J, Wagener AH, Wagers SS, Sterk PJ, Compton CH, Thorax 2011 66 910 917 10.1136/thx.2010.153643 21106547
18. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P, Lancet 2012 380 651 659 10.1016/S0140-6736(12)60988-X 22901886
19. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, Wallenstein GV, Zwillich SH, Kanik KS, N.Engl.J.Med 2012 367 495 507 10.1056/NEJMoa1109071 22873530
20. New targets for drug development in asthma. Adcock IM, Caramori G, Chung KF, Lancet 2008 372 1073 1087 10.1016/S0140-6736(08)61449-X 18805336
21. Asthma exacerbations: origin, effect, and prevention. Jackson DJ, Sykes A, Mallia P, Johnston SL, J.Allergy Clin.Immunol 2011 128 1165 1174 10.1016/j.jaci.2011.10.024 22133317